Unibest
← Back to patent-cliff list

CAS 19249-03-7

(ethane-1,2-diylbis(oxy))bis(ethane-2,1-diyl) bis(4-methylbenzenesulfonate)

Codes: ICOT-002

Application context (from source-drug indications)

Non-small cell lung cancerIcotinib HydrochlorideLung adenocarcinomaIcotinib HydrochlorideBronchial neoplasmIcotinib HydrochlorideLung cancerIcotinib HydrochlorideMetastatic breast cancerIcotinib HydrochloridePsoriasisIcotinib Hydrochloride

Source drugs (routes using this intermediate)

DrugTierExpiry
Icotinib HydrochlorideTier C — Watch / trade-

Position in synthesis routes (up/downstream chain)

Ordered by route registration; left → right is the synthesis direction. The highlighted node is the current CAS; others link to their own profiles.

Icotinib HydrochlorideOriginator routesteps: 6total yield: 20 mg

Intermediates available on this site

No listed intermediates for this target yet — send an RFQ directly and it will enter our matching pool.

This is a CAS-level registry record: registrations across routes are merged. Supplier offers and buyer demands will be matched on this CAS as the primary key.